NICOLE ODLUM: Open Payments
NPI 1669041067 · NEWBURGH, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 59 payments from 14 companies in 2025. Trend: 2023 $34 · 2024 $496 · 2025 $862
Food & beverage: $862
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $335 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $186 |
| Otsuka America Pharmaceutical, Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| PFIZER INC. | 2 | $37 |
| Novo Nordisk Inc | 2 | $31 |
| Exact Sciences Corporation | 1 | $29 |
| Corium, LLC | 1 | $19 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, UBRELVY, QULIPTA, REXULTI, Auvelity, PREVNAR 20, Wegovy.
Industry payments across IN — which companies pay providers there.
